Treatment of Vestibular Migraine : A Systematic Review and Meta-analysis
© 2020 The American Laryngological, Rhinological and Otological Society, Inc..
OBJECTIVE: To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM).
METHODS: Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta-analysis was performed on pre- and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement.
RESULTS: Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3 years with female-to-male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β-blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined.
CONCLUSIONS: Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side-effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta-analyses and for more evidence-based treatment of vestibular migraines. Laryngoscope, 131:186-194, 2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
The Laryngoscope - 131(2021), 1 vom: 21. Jan., Seite 186-194 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Byun, Young Jae [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dizziness |
|---|
| Anmerkungen: |
Date Completed 21.01.2021 Date Revised 21.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/lary.28546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306773228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306773228 | ||
| 003 | DE-627 | ||
| 005 | 20231225124116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lary.28546 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306773228 | ||
| 035 | |a (NLM)32083732 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Byun, Young Jae |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of Vestibular Migraine |b A Systematic Review and Meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.01.2021 | ||
| 500 | |a Date Revised 21.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The American Laryngological, Rhinological and Otological Society, Inc. | ||
| 520 | |a OBJECTIVE: To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM) | ||
| 520 | |a METHODS: Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta-analysis was performed on pre- and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement | ||
| 520 | |a RESULTS: Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3 years with female-to-male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β-blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined | ||
| 520 | |a CONCLUSIONS: Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side-effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta-analyses and for more evidence-based treatment of vestibular migraines. Laryngoscope, 131:186-194, 2021 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Vestibular migraine | |
| 650 | 4 | |a dizziness | |
| 650 | 4 | |a headache | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a vertigo | |
| 700 | 1 | |a Levy, Dylan A |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Shaun A |e verfasserin |4 aut | |
| 700 | 1 | |a Brennan, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Rizk, Habib G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Laryngoscope |d 1945 |g 131(2021), 1 vom: 21. Jan., Seite 186-194 |w (DE-627)NLM000205370 |x 1531-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2021 |g number:1 |g day:21 |g month:01 |g pages:186-194 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lary.28546 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2021 |e 1 |b 21 |c 01 |h 186-194 | ||